Back to Authors

Leavey, Patrick

0000-0002-0541-2536

Mayo Clinic

Children's Medical Center

Citations 3

Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group
Indelicato, Daniel J. , Callan, Alexandra K. , Krailo, Mark , DelRocco, Natalie , Buxton, Allen, Binitie, Odion , Christ, Alexander B. , Kessell, Sandy, Chuba, Paul J. , Nadel, Helen , Pawel, Bruce , DuBois, Steven G. , Janeway, Katherine A. , Leavey, Patrick J. , Mascarenhas, Leo , Ahmed, Safia K. , Binitie, Odion , Christ, Alexander B , DuBois, Steven G , Janeway, Katherine A , Leavey, Patrick , Mascarenhas, Leo , Laack, Nadia N Issa , Indelicato, Daniel J , Nadel, Helen , Görlick, Richard , Reed, Damon R. , Laack, Nadia N.

Pediatric Blood & Cancer | May 26, 2025 | Volume: 72 | Issue: 8 | Pages: No page available

10.1002/pbc.31820 Get It

AbstractPatients with resectable Ewing sarcoma (ES) in select sites, such as the pelvis or chest wall, have a higher risk of positive microscopic margins following surgery. AEWS1031 was the first North American/Australasia ES cooperative group trial allowing standardized preoperative radiotherapy, intended to minimize the morbidity of combined modality local tumor control as well as improve the likelihood of clear surgical margins. In this study, we found that the use of low‐dose preoperative radiation to a smaller target volume resulted in a high rate of R0 resection. The robust pathologic response rate strengthens existing evidence illustrating the radiosensitivity of Ewing sarcoma.
Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report
Leavey, Patrick J. , Laack, Nadia N. , Krailo, Mark D., Buxton, Allen, Randall, R. Lor , DuBois, Steven G. , Reed, Damon R. , Grier, Holcombe E., Hawkins, Douglas S. , Pawel, Bruce, Nadel, Helen , Womer, Richard B. , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Indelicato, Daniel J. , Wang, Dian, Marina, Neyssa , Janeway, Katherine A. , Mascarenhas, Leo , Gorlick, Richard , Janeway, Katherine A , Mascarenhas, Leo , Laack, Nadia N Issa , Hawkins, Douglas S , Reed, Damon R , Randall, Robert Lor , Indelicato, Daniel J , Leavey, Patrick , Krailo, Mark D., Buxton, Allen, DuBois, Steven G , Grier, Holcombe E., Pawel, Bruce, Nadel, Helen , Womer, Richard , Letson, G. Douglas, Bernstein, Mark, Brown, Kenneth, Maciej, Alexis, Chuba, Paul, Ahmed, Atif A., Wang, Dian, Marina, Neyssa

Journal of Clinical Oncology | October 15, 2021 | Volume: 39 | Issue: 36 | Pages: 4029-4038

10.1200/jco.21.00358 Get It

PURPOSE The primary aim of this phase III randomized trial was to test whether the addition of vincristine, topotecan, and cyclophosphamide (VTC) to interval compressed chemotherapy improved survival outcomes for patients with previously untreated nonmetastatic Ewing sarcoma. METHODS Patients were randomly assigned to receive standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles or experimental therapy with five cycles of VTC within the 17 cycles (regimen B). Patients were stratified by age at diagnosis (< 18 years and ≥18 years) and tumor site (pelvic bone, nonpelvic bone, and extraosseous). Tumor volume at diagnosis was categorized as < 200 mL or ≥ 200 mL. Local control occurred following six cycles. Histologic response was categorized as no viable or any viable tumor. Event-free survival (EFS) and overall survival (OS) were compared between randomized groups with stratified log-rank tests. RESULTS Of 642 enrolled patients, 309 eligible patients received standard and 320 received experimental therapy. The 5-year EFS and OS were 78% and 87%, respectively. There was no difference in survival outcomes between randomized groups (5-year EFS regimen A v regimen B, 78% v 79%; P = .192; 5-year OS 86% v 88%; P = .159). Age and primary site did not affect the risk of an EFS event. However, age ≥ 18 years was associated with an increased risk of death at 5 years (hazard ratio 1.84; 95% CI, 1.15 to 2.96; P = .009). The 5-year EFS rates for patients with pelvic, nonpelvic bone, and extraosseous primary tumors were 75%, 78%, and 85%, respectively. Tumor volume ≥ 200 mL was significantly associated with lower EFS. CONCLUSION While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.
Humanism and professionalism education for pediatric hematology‐oncology fellows: A model for pediatric subspecialty training
Kesselheim, Jennifer C. , Atlas, Mark, Adams, Denise M. , Aygün, Banu , Barfield, Ray, Eisenman, Kristen, Fulbright, Joy M. , Garvey, Katharine C. , Kersun, Leslie S. , Rao, Amulya Nageswara, Reilly, Anne, Sharma, Mukta , Shereck, Evan , Wang, Michael , Watt, Tanya , Leavey, Patrick J. , Nageswara Rao, Amulya, Rao, Amulya A. Nageswara , Leavey, Patrick

Pediatric Blood & Cancer | October 12, 2014 | Volume: 62 | Issue: 2 | Pages: 335-340

10.1002/pbc.25253 Get It

BackgroundHumanism and professionalism are virtues intrinsic to the practice of medicine, for which we lack a standard, evidence‐based approach for teaching and evaluation. Pediatric hematology‐oncology (PHO) fellowship training brings new and significant stressors, making it an attractive setting for innovation in humanism and professionalism training.ProcedureWe electronically surveyed a national sample of PHO fellows to identify fellows' educational needs in humanism and professionalism. Next, we developed a case‐based, faculty‐facilitated discussion curriculum to teach this content within pilot fellowship programs. We assessed whether fellowships would decide to offer the curriculum, feasibility of administering the curriculum, and satisfaction of fellow and faculty participants.ResultsSurveys were completed by 187 fellows (35%). A minority (29%) reported that their training program offers a formal curriculum in humanism and/or professionalism. A majority desires more formal teaching on balancing clinical practice and research (85%), coping with death/dying (85%), bereavement (78%), balancing work and personal life (75%), navigating challenging relationships with patients (74%), and depression/burn out (71%). These six topics were condensed into four case‐based modules, which proved feasible to deliver at all pilot sites. Ten fellowship programs agreed to administer the novel curriculum. The majority (90%) of responding fellows and faculty reported the sessions touched on issues important for training, stimulated reflective communication, and were valuable.ConclusionsPediatric hematology‐oncology fellows identify numerous gaps in their training related to humanism and professionalism. This curriculum offers an opportunity to systematically address these educational needs and can serve as a model for wider implementation. Pediatr Blood Cancer 2015;62:335–340. © 2014 Wiley Periodicals, Inc.